VP, Head of Pathology

This role is considered Hybrid.

Overview

This leader will join our Early Development team to lead the Pathology function. This position is onsite and will be located in Cambridge, MA.

Key Responsibilities

• Lead and manage pathologists and pathology laboratory functions to support a robust RNAi pipeline.
• Build and maintain a dynamic pathology group that provide both investigative and regulatory pathology support for both research (i.e., discovery/biology and Platform groups) and development stage programs at every stage of drug development.
• Oversight of GLP peer reviews, external due diligence, and support of global regulatory interactions/submissions.
• Establish strong and productive cross-functional collaborations.
• Develop internal and external visibility as a leading pathology voice in the field of RNAi therapeutics.

Qualifications

• American/European College of Veterinary Pathologists (ACVP/ECVP) board certification
• Doctor of Veterinary Medicine (DVM) or relevant field. PhD is preferred.
• 15+ years of scientific research and/or clinical experience, with a minimum of 7 years of industry experience
• CTA, IND, BLA, and NDA experience is strongly desired
• Strong collaborative experience supporting Research and Development Project Teams
• Management and oversite experience, including veterinary and clinical pathology groups
• Excellent communication skills to message complex concepts to project teams, senior leadership, and regulators
• Ability to work independently, build productive cross-functional collaborations, manage conflict, and lead by example

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.